Purdue files suit to edge out generic Oxy competitor

Purdue Pharma sued Watson Pharmaceuticals this week, claiming the generic drug maker’s application to manufacture oxycodone hydrochloride extended-release tablets infringes on its patent for OxyContin. According to this article from Bloomberg Businessweek, though the U.S. Food and Drug Administration won’t approve Watson’s application until the case is cleared up, the agency did sign off on the company’s generic form of oxycodone and aspirin. Of course, this is not the first generic opioid painkiller Purdue has tried to edge out of the market to protect its $3.1 billion-per-year pill – and as longs as profits sore for the privately-held company, it certainly won’t be the last.

Read about other OxyContin spin-offs here.

About Dana Owens

Dana Owens is San Francisco-based writer, editor and blogger who works on diverse projects from holistic health research to record label promotion. In addition to lending her editorial eye to Oxy Watchdog, Dana also acts as copyeditor for 99 Series, Inc. and executive assistant/project coordinator for Heartline Productions.
This entry was posted in Pharmaceutical Industry and tagged , , , , , , , , , , . Bookmark the permalink.

2 Responses to Purdue files suit to edge out generic Oxy competitor

  1. Pingback: Purdue continues to protect $3 billion patent on OxyContin | Oxy Watchdog

  2. Pingback: Third time is the charm: Purdue sues for OxyContin patent | Oxy Watchdog

Leave a Reply

Your email address will not be published. Required fields are marked *